Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 975-988

  Topkis, Stuart ^a,d   Swarz, Herbert ^b   Breisch, Sally A ^c   Maroli, Allan N ^c  

^a Private Practice   (United States)

^b Intl Pharmaceutical Consult Inc   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d NONE   (United States)

Author keywords

Community acquired pneumonia; Fluoroquinolone; Grepafloxacin

Indexed keywords

GREPAFLOXACIN;

ARTICLE; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HUMAN; LEGIONELLA PNEUMOPHILA; MAJOR CLINICAL STUDY; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NAUSEA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; TREATMENT OUTCOME;

EID: 0030670348     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80050-1     Document Type: Article

References (19)

1. LaForce M. Approaches to the patient with pleuropulmonary infection. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. New York: WB Saunders; 1992:460-485.
2. Bartlett JG, Mundy LM. Community-acquired pneumonia. NEJM. 1995;333: 1618-1625.
3. Marston BJ. Epidemiology of community-acquired pneumonia. Infect Dis Clin Pract. 1994;4(Suppl):S232-S239.
4. Lister PD. Multiply-resistant pneumococcus: Therapeutic problems in the management of serious infections. Eur J Clin Microbiol Infect Dis. 1995;14(Suppl 1): 18-25.
5. Doern GV, Brueggemann AB, Pierce G, et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study. Antimicrob Agents Chemother. 1997;41:292-297.
6. Whitson B, Campbell GD. Community-acquired pneumonia: New outpatient guidelines based on age. severity of illness. Geriatrics. 1994;49:24-36.
7. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. NEJM. 1997;336:243-250.
8. Vogel F. A guide to the treatment of lower respiratory tract infections. Drugs. 1995; 50:62-72.
9. Niederman MS, Bass JB, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418-1426.
10. Imada T, Miyazaki S, Nishida M, et al. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother. 1992;36:573-579.
11. Spangler SK, Jacobs MR, Pankuch GA, Appelbaum PC. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, RO 23-9424 and RP 67829. J Antimicrob Chemother. 1993;31:273-280.
12. Sewell DL, Barry AL, Allen SD, et al. Tentative interpretive criteria for testing susceptibility of Streptococcus pneumoniae to eight fluoroquinolones. Diagn Microbiol Infect Dis. 1996;26:23-27.
13. Sader HS, Erwin ME, Jones RN. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. Eur J Clin Microbiol Infect Dis. 1992;11: 372-381.
14. Wise R, Andrews JM, Brenwald N. The in vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother. 1993;31:497-504.
15. Data on file. Glaxo Wellcome.
16. Ferguson J, Dawe R. Phototoxicity in quinolones: Comparison of ciprofloxacin and grepafloxacin. J Antimicrob Chemother. In press.
17. Wakabe H, Mitsuhashi S. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother. 1992;36:2185-2191.
18. Neu HC, Fang W, Gu JW, Chin NX. In vitro activity of OPC-17116. Antimicrob Agents Chemother. 1992;36:1310-1315.
19. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.